Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decitabine + nivolumab + tetrahydrouridine
- Development stage
- Phase 2
- Lead developer
- Case Comprehensive Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of decitabine, nivolumab, and tetrahydrouridine. Decitabine depletes DNA methyltransferase 1 (DNMT1), an enzyme often increased in cancer that suppresses neo-antigen expression. Tetrahydrouridine (THU) blocks cytidine deaminase, an enzyme that rapidly breaks down decitabine, thereby increasing the time cancer cells are exposed to decitabine. Nivolumab is an immune checkpoint inhibitor that blocks PD-1, enhancing T-cell immune response against cancer cells. This combination aims to overcome the limitations of using these drugs individually, particularly for solid tumors like non-small cell lung cancer (NSCLC).
- Other names
- THU-Dec/anti-PD1
02
Targets
CDA (Cytidine deaminase)DNMT1 (DNA (cytosine-5)-methyltransferase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on decitabine + nivolumab + tetrahydrouridine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decitabine + nivolumab + tetrahydrouridine.